Digital Dose Inhalers - Market Insights, Competitive Landscape, and Market Forecast - 2030

Digital dose inhalers market by product type (dry powder inhalers and metered dose inhalers), by application (chronic obstructive pulmonary disease, asthma, and others), and by geography is expected to advance at a respectable CAGR forecast till 2027 owing to the accelerating prevalence of respiratory disorders such as asthma, copd, and others, the rising air pollution, and the growing number of product development activities such as product launches and regulatory approvals across the globe.

The global digital dose inhalers market will grow at a CAGR of 11.27% during the forecast period from 2022 to 2027. The digital dose inhalers market is witnessing significant market growth due to the factors such as the rising prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others. Furthermore, the surging adoption of digital technology by key pharmaceutical players, the rising air pollution, increase in the population of smokers, and increasing exposure to dust, fumes, and airborne particles will spur the market of digital dose inhalers. Additionally, the growing technological advancements such as recent product launches and regulatory approvals is expected to drive the overall market for digital dose inhalers during the forecast period (2022-2027). Therefore, the market for digital dose inhalers is estimated to grow at a substantial CAGR during the forecast period from 2022 to 2027.

DIGITAL DOSE INHALERS MARKET DYNAMICS:

One of the key aspect for driving the digital dose inhalers market is the rising prevalence of various respiratory disorders globally.

For instance, as per data by the World Health Organization (WHO) 2022, asthma affected approximately nearly 262 million people in 2019, causing 455,000 deaths in the same year, globally.

Also, according to data by the Global Burden of Disease Study (2019), there were 212.3 million prevalent cases of COPD reported globally, accounting for 3.3 million deaths in the year 2019. In addition to asthma and COPD, the numbers for cystic fibrosis are constantly on the rise. As per data by the March of Dimes Organization (2019), about 70,000 to 100,000 people had cystic fibrosis in the year 2019 globally, affecting males and females at the same rate.

Moreover, the rising air pollution is also expected to drive the demand for digital dose inhalers in the upcoming years. For instance, as per the Organization for Economic Co-operation and Development 2022, by 2050 the emission of global greenhouse gases (GHGs) could be anticipated to increase by about 50%, majorly owing to 70% growth in energy-related CO2 emissions. It also stated that the atmospheric concentration of GHGs could reach 685 parts per million (ppm) CO2- equivalents by 2050, resulting in the global average temperatures to be 3 to 6 degree Celsius above the pre-industrial levels by the end of the century.

Along with the factors mentioned above, the number of technological developments are constantly increasing, bolstering the growth of the digital dose inhalers market. For instance, in February 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced the launch of HeroTracker® Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device.

Therefore, the factors stated above collectively will drive the overall digital dose inhalers market during the forecast period from 2022-2027.

However, high cost of the devices, concerns regarding the accuracy of digital data, and others may prove to be challenging factors for digital dose inhalers market growth.

The COVID- 19 pandemic had a slightly negative impact on the market growth of digital dose inhalers during the initial few months owing to the lockdown impositions, border closures, and others leading to disruption in the manufacturing, supply, import, export, and other related activities of the digital dose inhalers market. Also, owing to the fear of spread of SARS-CoV-2 virus which is the causative agent for COVID-19 and uncertainties revolving around the pandemic, many countries across the world were forced to close down pulmonary function tests (PFT) laboratories except in case of emergencies. However, people suffering from moderate-to-severe or uncontrolled asthma were more likely to get hospitalized from COVID-19. The COVID -19 pandemic also led to rise in digital dose inhalers in the later half owing to the awareness and concerns regarding lung health among the people across the world which is further accelerated the utilization of respiratory inhalers such as digital or smart inhalers for the testing of lung function, driving the market growth for digital dose inhalers. Moreover, with the commencement of e-commerce availability of digital dose inhalers, increased its demand in the market. Thus, along with the above-mentioned factors, high vaccination rates and relaxations in the government-imposed lockdown, the demand for digital dose inhalers is subjected to increase driving the overall market for digital dose inhalers during the forecast period of 2022 - 2027.

DIGITAL DOSE INHALERS MARKET SEGMENT ANALYSIS:

Digital Dose Inhalers Market by Product Type (Dry Powder Inhalers and Metered Dose Inhalers), Application (Chronic Obstructive Pulmonary Disease, Asthma, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product type segment of the digital dose inhalers market, the dry powder inhalers segment is expected to have a significant revenue share in the year 2021. This was primarily owing to the increasing prevalence of respiratory diseases, increasing technological advancements pertaining to the device, and surging launches by the key players in the market.

For instance, dry powder inhalers (DPI's) in general are easier to use than the metered dose inhalers (MDI) and cause fewer irritant effects.

Moreover, concerns related to the incidences of drug irritation caused by the presence of propellant components, such as chlorofluorocarbons (CFCs) in metered dose inhalers, have favored the adoption of the dry powder inhalers, with fewer irritant effects while delivering comparable therapeutic efficacy as metered dose inhalers. Thus, the dry powder inhalers are also known as propellant free inhalers.

Further, the DPI deposit the medicine in the lungs at a much higher rate than MDIs. This makes them more efficient and effective as they can provide a higher quantity of medicine with a single dose.

Additionally, the increasing product launches are also expected to contribute to the growth of the studied segment during the forecast period. For instance, in December 2020, Berry Global launched the RS01 single-dose dry powder inhaler with built-in sensors and digital capabilities. The RS01 tracks inhaler use and connects to a companion app that provides personalized guidance to improve adherence and inhaler technique.

Therefore, owing to the advantages associated with dry powder inhaler and increasing product launches, the category is expected to witness a considerable growth eventually contributing to the overall growth of the global digital dose inhalers market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL DIGITAL DOSE INHALERS MARKET:

Among all the regions, North America is expected to dominate the global digital dose inhalers market in the year 2021 and is expected to do the same during the forecast period from 2022-2027. This can be ascribed to the escalating prevalence of various respiratory disorders, increasing burden of geriatric population prone to respiratory disorder, and the presence of key market players in the region are another factors which acts as a supportive factor for the North America's digital dose inhalers market growth.

As per the data published by World Health Organization (WHO) 2021, approximately 25 million people in the United States had asthma in the year 2020 including 4.2 million children, which equals about 1 in every 13 people.

Moreover, according to the National Center for Health Statistics 2019-2020, stated that the percentage of COPD, emphysema, or chronic bronchitis for adults aged 18 and over, in the United States, increased from 4.6% in 2019 to 5.0% in 2020.

In other countries of North America such as Canada, the numbers for respiratory ailments are substantially increasing. According to statistics by the Lung Association 2020-2021, it was concluded that about 2.6 million Canadians were living with asthma in the year 2020 - 2021.

Thus, from the above sources and statistics it can be concluded that the respiratory disorders are increasing in the North America, ultimately increasing the demand of digital dose inhalers in the market.

Additionally, as per the New Mexico Department of Health Epidemiology and Response Division, 2019, in the year 2021, approximately 16.0% of adults were current smokers and nearly 32.7% of high school students were current smokers. The increasing consumption of smoking will increase the risk of developing respiratory disorders or lung cancer, ultimately increasing the demand of digital dose inhalers in order to treat and manage the respiratory disorders.

Furthermore, the increasing product launches, regulatory approvals, acquisitions, partnerships, and other activities by key players in the region will drive the market of digital dose inhalers in the upcoming years. For instance, in July 2020, Teva Pharmaceuticals, one of the prominent player in healthcare industries, announced the launch of its ProAir Digihaler in the United States. It is used in people ≥4 years old to treat or prevent bronchospasm in people who have reversible obstructive airway disease or to prevent exercise-induced bronchospasm.

Henceforth, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the digital dose inhalers market.

DIGITAL DOSE INHALERS MARKET KEY PLAYERS:

Some of the key market players operating in the digital dose inhalers market includes Glenmark Pharmaceuticals, Novartis AG, ResMed, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., H&T Presspart Manufacturing Ltd., AptarGroup, Inc., Amiko Digital Health Limited., Trudell Medical UK Limited, BreatheSuite Inc., Opko Health, Inc., Cipla Inc., Sensirion AG, 3M, adherium, and others.

RECENT DEVELOPMENTAL ACTIVITIES IN DIGITAL DOSE INHALERS MARKET:

• In February 2022 Astrazeneca and Honeywell partnered to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less global warming potential than propellants currently used in respiratory medicines.
• In February 2019, Propeller Health, delivering one of the digital respiratory health platform, signed a partnership with Orion Corporation in order to bring the Propeller's products among European patients.

KEY TAKEAWAYS FROM THE DIGITAL DOSE INHALERS MARKET REPORT STUDY

• Market size analysis for current digital dose inhalers market size (2020), and market forecast for 5 years (2021-2027)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the digital dose inhalers market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global digital dose inhalers market.
• Various opportunities available for the other competitor in the digital dose inhalers market space.
• What are the top performing segments in 2020? How these segments will perform in 2027.
• Which is the top-performing regions and countries in the current digital dose inhalers market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for digital dose inhalers market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS DIGITAL DOSE INHALERS MARKET REPORT STUDY

• Digital dose inhalers products providers
• Research organizations and consulting companies
• Digital dose inhalers -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in digital dose inhalers
• Various end users who want to know more about the digital dose inhalers market and latest technological developments in the digital dose inhalers market.

FREQUENTLY ASKED QUESTIONS FOR DIGITAL DOSE INHALERS MARKET:

1. What are digital dose inhalers?

The digital dose inhalers are devices that deliver a specific amount of medication to the lungs in the form of aerosolized medicine or dry powder. These inhalers have built-in sensors that detect use of inhaler and measure respiratory flow, according to the release and dose management.

2. What is the global market for digital dose inhalers?

The global digital dose inhalers market will grow at a CAGR of 11.27% during the forecast period from 2022 to 2027.

3. What are the drivers for global digital dose inhalers market?

The digital dose inhalers market is witnessing a positive market growth owing to the factors such as increasing of prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others. Further, the surge in the adoption of digital technology by key pharmaceutical players, rising air pollution, and increase in the population of smokers will aid in driving the market of digital dose inhalers. Also, the increasing product launches and regulatory approvals will create an exigency for the digital dose inhalers market.

4. Who are the key players operating in the global digital dose inhalers market?

Some of the key market players operating in the digital dose inhalers market includes Glenmark Pharmaceuticals, Novartis AG, ResMed, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., H&T Presspart Manufacturing Ltd., AptarGroup, Inc., Amiko Digital Health Limited., Trudell Medical UK Limited, BreatheSuite Inc., Opko Health, Inc., Cipla Inc., Sensirion AG, 3M, adherium, and others.

5. Which region has the highest share in digital dose inhalers market?

Among all the regions, North America is estimated to amass the significant revenue share in the global digital dose inhalers market. This can be ascribed to the escalating prevalence of various respiratory disorders, increasing burden of geriatric population prone to respiratory disorder, and the presence of key market players in the region are another factors which acts as a supportive factor for the North America's digital dose inhalers market growth.


This product will be delivered within 2 business days.